Tablet Splitting and Analytical Technologies - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Tablet Splitting and Analytical Technologies
Tim Freeman of Freeman Technology explains how new analytical technologies have influenced quality criteria and standards for the uniformity of dosage units, and why more accurate systems are leading to greater focus on tablet scoring.



How has the development of new analytical technologies influenced the quality criteria and standards for the uniformity of dosage units? Have more accurate systems led to greater focus on tablet scoring?

Tablet scoring enables patients to control their drug dosage and could potentially deliver cost savings for healthcare providers. It also makes larger tablets easier to swallow. However, the production of a scored tablet undoubtedly adds complexity to the manufacturing process. This issue was brought into focus by recent FDA guidance on tablet scoring, for both general tabletting, and more specifically, the manufacturing of generics.

Whilst a key aspect of tablet splitting has always been on how uniformly the active ingredient is distributed within the finished product, it is equally important to understand how to produce tablets with the required mechanical integrity and properties. Advances in spectroscopic techniques, such as near infrared (NIR) and laser-induced breakdown spectroscopy (LIBS), mean that it is now possible to analyse content uniformity across the surface of a tablet. In addition, advances in powder characterisation techniques can assist in the development of truly robust manufacturing processes.

Poor content uniformity is often attributed to the difficulty of achieving a homogeneous blend to begin with, which may be because the active ingredient is present at very low levels, or is cohesive and prone to agglomeration. Alternatively, if the API has significant particle size or density difference to the excipients in the blend, it may be liable to segregation post blending. Dynamic powder characterisation can help optimise the blending process (1) and also predict the likelihood of segregation. It therefore brings real insight into how to address these issues.

Furthermore, dynamic parameters in combination with shear and bulk properties, support a comprehensive understanding of powder behaviour, whether during the blending process itself, or when processed through the tablet press. Together these properties help manufacturers to rationalise and control powder performance during discharge from the hopper, whilst flowing through the feed frame, and during filling of the die. In addition, they provide information relating to the compressibility characteristics of the blend, as well as quantifying the ease with which air is entrained and released, both of which impact finished tablet quality. This information can be extremely helpful in ensuring compatibility between the process equipment selected and the properties of the blend, a match that is crucial for ensuring content uniformity in scored tablets.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
22%
Attracting a skilled workforce
30%
Obtaining/maintaining adequate financing
11%
Regulatory compliance
37%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here